A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of MRG-110 Following Local Intradermal Injection After Skin Excisional Wound Creation in Normal Healthy Volunteers

Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of MRG-110 Following Local Intradermal Injection After Skin Excisional Wound Creation in Normal Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Aug 2018

At a glance

  • Drugs MRG-110 (Primary)
  • Indications Heart failure; Ischaemia; Wounds
  • Focus Adverse reactions
  • Sponsors miRagen Therapeutics
  • Most Recent Events

    • 01 May 2018 Status changed from planning to recruiting, according to a miRagen Therapeutics media release.
    • 27 Apr 2018 According to a miRagen Therapeutics media release, this study may initate in the second quarter of 2018 in collaboration with Servier.
    • 03 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top